Thromb Haemost:你所担心的华法林药物相互作用 小题大做?

2018-05-09 吴星 环球医学

华法林是目前临床上应用最广泛的口服抗凝药之一。由于药物的有效性和出血风险均与国际标准化比值(INR)水平相关,因此华法林患者必须定期进行血液检测以监测该参数。华法林与其他众多药物的相互作用更是增加了治疗的复杂性。临床医生和患者在使用华法林联合其他药物时常常面临复杂的决策,这种情况在老年患者中尤为常见。

华法林是目前临床上应用最广泛的口服抗凝药之一。由于药物的有效性和出血风险均与国际标准化比值(INR)水平相关,因此华法林患者必须定期进行血液检测以监测该参数。华法林与其他众多药物的相互作用更是增加了治疗的复杂性。临床医生和患者在使用华法林联合其他药物时常常面临复杂的决策,这种情况在老年患者中尤为常见。

目前关于华法林药物-药物相互作用的大部分知识来源于病例报告和小规模病例系列,尽管可用于提醒临床医生注意潜在的治疗误区,但也有一些不足之处,并且不足以代表普通人群量化的临床影响。2018年3月,发表在《Thromb Haemost》的一项研究调查了既往报道的华法林和其他药物的相互作用对国际标准化比值(INR)人群水平的影响。

在该项研究中,使用健康促进网络(THIN;一个英国初级医疗数据库),研究人员随访了一个2005~2013年华法林使用者的队列(N=121962人),直到对第一个潜在相互作用药物的合格处方进行评估。

研究人员确定了16个子队列,其中每个研究药物为1个队列,还有1个华法林对照子队列。

使用配对学生t检验,通过比较相互作用的药物初始给药前和初始给药后测量的INR值,评估INR水平的短期变化。研究人员也评估了INR值处于治疗范围外(INR:2~3)的患者比例。

结果显示,咪康唑使用与INR平均增加最高相关(+3.35),其次是胺碘酮(+1.28)、氟康唑(+0.79)、甲硝唑(+0.75)和制霉菌素(+0.65)。减去对照子队列中观察到的天然INR差异后,分别在初始使用咪康唑(53.2%)、胺碘酮(45.5%)、甲硝唑(23.3%)、氟康唑(23.2%)和制霉菌素(17.6%)的患者中观察到INR超过治疗水平(INR>3)。

卡马西平使用与INR平均降低-0.63相关,并且46.2%的卡马西平初始使用患者观察到亚治疗水平(INR<2)。

对于所有其他药物,INR改变为小至中等,其中INR改变的绝对单位为+0.23~+0.55,INR水平超过治疗范围的患者比例<16%。

作者认为,多种研究药物都观察到了临床潜在重要的相互作用。虽然经过证实,但在校正标准INR变异后,多数药物对华法林使用者普通人群的影响都非常小。

尽管如此,我们在华法林联合其他药物时仍然不能掉以轻心,要密切关注药物-药物相互作用。

原始出处:

Martín-Pérez M, Gaist D, de Abajo FJ, et al. Population Impact of Drug Interactions with Warfarin: A Real-World Data Approach. Thromb Haemost. 2018 Mar;118(3):461-470. doi: 10.1055/s-0038-1627100.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2008360, encodeId=1bd120083607a, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Feb 13 07:10:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909240, encodeId=785619092406f, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Oct 28 22:10:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471585, encodeId=0c9d14e1585cd, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri May 11 04:10:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585018, encodeId=604e1585018e0, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Fri May 11 04:10:00 CST 2018, time=2018-05-11, status=1, ipAttribution=)]
    2019-02-13 changfy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2008360, encodeId=1bd120083607a, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Feb 13 07:10:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909240, encodeId=785619092406f, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Oct 28 22:10:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471585, encodeId=0c9d14e1585cd, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri May 11 04:10:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585018, encodeId=604e1585018e0, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Fri May 11 04:10:00 CST 2018, time=2018-05-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2008360, encodeId=1bd120083607a, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Feb 13 07:10:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909240, encodeId=785619092406f, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Oct 28 22:10:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471585, encodeId=0c9d14e1585cd, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri May 11 04:10:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585018, encodeId=604e1585018e0, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Fri May 11 04:10:00 CST 2018, time=2018-05-11, status=1, ipAttribution=)]
    2018-05-11 ylz8405
  4. [GetPortalCommentsPageByObjectIdResponse(id=2008360, encodeId=1bd120083607a, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Feb 13 07:10:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909240, encodeId=785619092406f, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Oct 28 22:10:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471585, encodeId=0c9d14e1585cd, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri May 11 04:10:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585018, encodeId=604e1585018e0, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Fri May 11 04:10:00 CST 2018, time=2018-05-11, status=1, ipAttribution=)]

相关资讯

2016十大精选病例,经典、疑难、实用

01.【用药警示】“凶险”的甘草片本例患者系长期、大量使用甘草片代替毒品服用,从而造成高血压及一系列心、肾功能的损害。目前有部分吸毒人员滥用甘草片等药品,故需提醒临床医护人员高度重视,应详细询问病史,注意相关病例。同时,在使用甘草片时,应密切观察,发现异常及时停药,并采取相应的治疗措施。02.【病例】19岁女孩血压高达180,病因竟是它对于青少年高血压,首先需要排除继发性因素,除了大量与肥胖等代谢

JAHA:瓣膜性心脏病合并AF:NOAC vs华法林

非维生素K拮抗剂是一种新型的口服抗凝剂,那么非维生素K拮抗剂口服抗凝剂(NOACs)能代替维生素K拮抗剂华法林进行治疗吗?2017年7月,发表在《J Am Heart Assoc》上的一项系统评价和荟萃分析调查了NOACs与华法林对心房颤动(AF)合并瓣膜性心脏病(VHD)患者的影响。